about
Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitisToll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesTargeting Syk in Autoimmune Rheumatic DiseasesB-cell receptor signalling and its crosstalk with other pathways in normal and malignant cellsEssential role of the zinc transporter ZIP9/SLC39A9 in regulating the activations of Akt and Erk in B-cell receptor signaling pathway in DT40 cellsTyrosine kinase inhibitors for the treatment of rheumatoid arthritisANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain libraryThe SLE variant Ala71Thr of BLK severely decreases protein abundance and binding to BANK1 through impairment of the SH3 domain function.The Dok-3/Grb2 protein signal module attenuates Lyn kinase-dependent activation of Syk kinase in B cell antigen receptor microclustersRegulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).The autoinhibitory C-terminal SH2 domain of phospholipase C-γ2 stabilizes B cell receptor signalosome assembly.Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages.Complex phosphorylation dynamics control the composition of the Syk interactome in B cells.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.Diacylglycerol kinase ζ limits B cell antigen receptor-dependent activation of ERK signaling to inhibit early antibody responsesSuppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone miceInhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.Outer membrane protein A (OmpA) of Shigella flexneri 2a induces TLR2-mediated activation of B cells: involvement of protein tyrosine kinase, ERK and NF-κB.HGAL localization to cell membrane regulates B-cell receptor signaling.Bruton's TK inhibitors: structural insights and evolution of clinical candidates.Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function.The E3 ubiquitin ligase Mule acts through the ATM-p53 axis to maintain B lymphocyte homeostasis.A computational model for early events in B cell antigen receptor signaling: analysis of the roles of Lyn and Fyn.Whole-genome bisulfite DNA sequencing of a DNMT3B mutant patientA Computational Study of the Effects of Syk Activity on B Cell Receptor Signaling DynamicsDifferences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.Prolonged production of reactive oxygen species in response to B cell receptor stimulation promotes B cell activation and proliferation.Elevated BCR signaling and decreased survival of Lyn-deficient transitional and follicular B cells.Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes.Formation of BCR oligomers provides a mechanism for B cell affinity discrimination.Chronic lymphocytic leukemia therapy: new targeted therapies on the wayCritical role of B cell lymphoma 10 in BAFF-regulated NF-κB activation and survival of anergic B cells.Focal adhesion kinase negatively regulates Lck function downstream of the T cell antigen receptor.Genetics of rheumatic disease.The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity.Overview of the immune response.Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia.Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity.
P2860
Q24623805-5CD4C92A-8A36-4E6C-ABD2-5392CDBA91BAQ24624348-4A4AEC3E-2D9E-44C2-B2D7-718E6511C6C9Q26751042-FE85761B-4EFD-47E3-8897-4B2211C75AB1Q28245018-5B353B3D-BB1E-461C-BBFF-F945CF2B6388Q28487787-99B0E7D1-2259-427E-BF9D-1CA544B5146DQ28674280-19FFE3CC-E1B0-4446-8C04-2B0415C6DB1EQ30008753-4852E132-769B-478A-A7EC-DF8D24D2B400Q30009028-B9DAB2E8-EF91-4F42-AB33-38E2300007E9Q30009963-56A1E0AB-7C73-427A-9AF0-7AFDDE894101Q30010124-E5D1E6BF-1EE9-455B-93BC-5304EE94C914Q30588609-A3F267C9-37C1-434A-A760-62C34AAFF28FQ33806012-DCA697C4-8DD4-42AD-9423-32F2A2FE3350Q33863904-EBA05DA9-C72F-43F4-BA2E-87B844C29A49Q33889168-A04697C9-4D1D-423B-A595-D9E64D2A4EACQ33940462-32C574C2-6714-47DE-B8E8-15B0C68ED138Q33987268-813843FC-ACB0-45DA-975D-C5AE4C853934Q34042407-9E943D13-A8D3-4C64-B4E4-6D5F0202B9BAQ34294123-0BE60BC9-D670-4F10-9E57-CBD0A70EC421Q35004959-397D556C-106F-494A-B132-840620603085Q35181271-C0F64BAC-4C16-4A62-BCF5-4BC802BE61A3Q35649750-0B26C95E-193C-48CF-AF37-5F36AEB9AB7BQ35679564-64CF6FA9-8BFC-4EDD-A7A6-2722DF01489AQ36084264-07A7BB35-B40D-4BC1-9044-F8F7EE3BCAE4Q36100964-EEC4C68F-BBB7-4F76-9DE4-FB475D467577Q36233264-7224C380-48E2-4AF3-8744-26A7FAD962DDQ36305333-F0FAFF60-F8B0-424E-91DF-BC75AD528CB7Q36448748-86DB4D54-76E8-4069-8F46-8736654CDE98Q36453064-077AC123-2E8F-4E82-AC1E-2E2BFDAF1E86Q36514204-D2E3F1B8-D61F-4F8C-B274-A957C9BE66FAQ36975865-D8AD6C1C-57A4-443B-9CC3-4D8EEE6F731CQ37113544-F16642FD-82B5-48D9-8A18-F0C9631A2023Q37207024-5D312ACF-B8FD-4DED-BEDB-2634645A89CCQ37398394-C98E2B43-E46C-4712-818E-8D7BA5E3E237Q37453992-2E6865D0-1046-44D0-B1B6-E02A0A315EF3Q37630230-FCF64892-ACCD-40DC-8A95-A141382E62C1Q37696715-EBD367AC-127E-4308-BB0C-EB10602CCBC0Q37742056-3E1BC59F-B305-4557-91F8-328C5F856EEDQ37787243-EC7BD9D8-647D-47C6-AD09-B279D0EBFAA2Q37826463-E59893D4-AECA-4758-92AF-F7C8E711D0A9Q38034270-DF4A8C3F-29E8-4D3F-B979-BE91116FBE73
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Tyrosine kinases and their substrates in B lymphocytes.
@ast
Tyrosine kinases and their substrates in B lymphocytes.
@en
Tyrosine kinases and their substrates in B lymphocytes.
@nl
type
label
Tyrosine kinases and their substrates in B lymphocytes.
@ast
Tyrosine kinases and their substrates in B lymphocytes.
@en
Tyrosine kinases and their substrates in B lymphocytes.
@nl
prefLabel
Tyrosine kinases and their substrates in B lymphocytes.
@ast
Tyrosine kinases and their substrates in B lymphocytes.
@en
Tyrosine kinases and their substrates in B lymphocytes.
@nl
P2860
P1476
Tyrosine kinases and their substrates in B lymphocytes.
@en
P2093
Masaki Hikida
Tomohiro Kurosaki
P2860
P304
P356
10.1111/J.1600-065X.2008.00748.X
P577
2009-03-01T00:00:00Z